pioglitazone has been researched along with Overweight in 17 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 kg/m(2)) were randomly assigned to one of four intervention groups: pioglitazone or placebo and resistance training (RT) or no RT, while undergoing intentional weight loss via a hypocaloric diet." | 9.17 | Resistance training and pioglitazone lead to improvements in muscle power during voluntary weight loss in older adults. ( Carr, JJ; Isom, S; Kritchevsky, SB; Lyles, MF; Marsh, AP; Miller, GD; Miller, ME; Nicklas, BJ; Shea, MK; Vance Locke, RM, 2013) |
| "To evaluate the effect of a thiazolidinedione, pioglitazone, on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance." | 9.12 | Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance. ( González-Ortiz, M; Hernández-Salazar, E; Kam-Ramos, AM; Martínez-Abundis, E, 2007) |
| "To evaluate the effects of pioglitazone on insulin sensitivity and levels of biomarkers associated with thrombotic risk in overweight and obese, non-diabetic subjects with coronary artery disease." | 9.12 | Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease. ( Dodis, R; Francis, CW; Gerich, JE; Kaba, NK; Lee, M; Messing, S; Mieszczanska, H; Phipps, RP; Schwarz, KQ; Smith, BH; Taubman, MB, 2007) |
| " This work investigated the protective effect of pioglitazone on myocardial infarction (MI) in non-diabetic and diabetic rats, focusing on its role on advanced glycated endproducts (AGEs) and cardiac apoptotic machinery." | 7.83 | Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE-RAGE axis and inhibition of apoptosis. ( Farag, NE; Khodeer, DM; Moustafa, YM; Zaitone, SA, 2016) |
| " However, the effects of pioglitazone in overweight patients with myotonic dystrophy and type 2 diabetes mellitus have not been established." | 7.75 | Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy. ( Abe, H; Funayama, T; Hirose, T; Ikeda, F; Kaga, H; Kanazawa, A; Kawamori, R; Kudo, K; Mita, T; Tokoro, M; Watada, H, 2009) |
| "Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0." | 6.77 | Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. ( Buck, M; Chojkier, M; Donohue, M; Elkhayat, H; Sabry, D, 2012) |
| "5 kg/m(2)) were randomly assigned to one of four intervention groups: pioglitazone or placebo and resistance training (RT) or no RT, while undergoing intentional weight loss via a hypocaloric diet." | 5.17 | Resistance training and pioglitazone lead to improvements in muscle power during voluntary weight loss in older adults. ( Carr, JJ; Isom, S; Kritchevsky, SB; Lyles, MF; Marsh, AP; Miller, GD; Miller, ME; Nicklas, BJ; Shea, MK; Vance Locke, RM, 2013) |
| "To assess the association of weight and weight change with mortality and non-fatal cardiovascular outcomes (hospitalisation, myocardial infarction and stroke) in T2DM patients with cardiovascular co-morbidity and the effect of pioglitazone-induced weight change on mortality." | 5.16 | Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. ( Anker, SD; Cairns, R; Clark, AL; Doehner, W; Dormandy, JA; Erdmann, E; Ferrannini, E, 2012) |
| "To evaluate the effect of a thiazolidinedione, pioglitazone, on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance." | 5.12 | Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance. ( González-Ortiz, M; Hernández-Salazar, E; Kam-Ramos, AM; Martínez-Abundis, E, 2007) |
| "To evaluate the effects of pioglitazone on insulin sensitivity and levels of biomarkers associated with thrombotic risk in overweight and obese, non-diabetic subjects with coronary artery disease." | 5.12 | Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease. ( Dodis, R; Francis, CW; Gerich, JE; Kaba, NK; Lee, M; Messing, S; Mieszczanska, H; Phipps, RP; Schwarz, KQ; Smith, BH; Taubman, MB, 2007) |
| " Because insulin resistance is an independent predictor of cardiovascular disease (CVD), this study was initiated to see if pioglitazone administration would improve insulin sensitivity and thereby decrease risk of CVD in overweight/obese, nondiabetic, insulin-resistant patients with untreated OSA." | 3.85 | Effect of Pioglitazone on Cardiometabolic Risk in Patients With Obstructive Sleep Apnea. ( Abbasi, F; Ariel, D; Cardell, J; Grove, K; Kim, SH; Kushida, CA; Lamendola, C; Liu, A; Mojaddidi, H; Patel, S; Reaven, GM; Tomasso, V; Tsao, PS; Xu, S, 2017) |
| " This work investigated the protective effect of pioglitazone on myocardial infarction (MI) in non-diabetic and diabetic rats, focusing on its role on advanced glycated endproducts (AGEs) and cardiac apoptotic machinery." | 3.83 | Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE-RAGE axis and inhibition of apoptosis. ( Farag, NE; Khodeer, DM; Moustafa, YM; Zaitone, SA, 2016) |
| "To investigate the recovery of thiazolidinedione-induced body weight gain and haematopoietic changes after stopping pioglitazone treatment in patients with Type 2 diabetes." | 3.80 | Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10-month withdrawal of pioglitazone in patients with Type 2 diabetes. ( Chen, BK; Feng, CC; Lee, MY; Lin, KD; Shin, SJ; Yu, ML, 2014) |
| " The purpose of this study was to determine whether pioglitazone stimulates adipogenesis in vivo and whether this process relates to improved insulin sensitivity." | 3.76 | Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue. ( Abbasi, F; Cushman, SW; Lamendola, C; Liu, T; McLaughlin, TM; Reaven, GM; Sherman, A; Tsao, P; Yee, G, 2010) |
| " However, the effects of pioglitazone in overweight patients with myotonic dystrophy and type 2 diabetes mellitus have not been established." | 3.75 | Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy. ( Abe, H; Funayama, T; Hirose, T; Ikeda, F; Kaga, H; Kanazawa, A; Kawamori, R; Kudo, K; Mita, T; Tokoro, M; Watada, H, 2009) |
| "Pioglitazone treatment led to a significant 3% body mass increase." | 2.90 | Effect of pioglitazone treatment on brown adipose tissue volume and activity and hypothalamic gliosis in patients with type 2 diabetes mellitus: a proof-of-concept study. ( Cendes, F; Cintra, RM; de-Lima-Júnior, JC; Folli, F; Monfort-Pires, M; Rachid, B; Ramos, CD; Rodovalho, S; Van de Sande-Lee, S; Velloso, LA, 2019) |
| "Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0." | 2.77 | Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. ( Buck, M; Chojkier, M; Donohue, M; Elkhayat, H; Sabry, D, 2012) |
| "Insulin resistance is a common problem in obese patients with type 2 diabetes." | 2.72 | Improvement of glycemic control after a 3-5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy. ( Biesenbach, G; Grafinger, P; Raml, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 12 (70.59) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de-Lima-Júnior, JC | 1 |
| Rodovalho, S | 1 |
| Van de Sande-Lee, S | 1 |
| Monfort-Pires, M | 1 |
| Rachid, B | 1 |
| Cintra, RM | 1 |
| Ramos, CD | 1 |
| Cendes, F | 1 |
| Folli, F | 1 |
| Velloso, LA | 1 |
| Robakis, TK | 1 |
| Watson-Lin, K | 1 |
| Wroolie, TE | 1 |
| Myoraku, A | 1 |
| Nasca, C | 1 |
| Bigio, B | 1 |
| McEwen, B | 1 |
| Rasgon, NL | 1 |
| Raccah, D | 1 |
| Gourdy, P | 1 |
| Sagnard, L | 1 |
| Ceriello, A | 1 |
| Lin, KD | 1 |
| Lee, MY | 1 |
| Feng, CC | 1 |
| Chen, BK | 1 |
| Yu, ML | 1 |
| Shin, SJ | 1 |
| Irving, BA | 1 |
| Carter, RE | 1 |
| Soop, M | 1 |
| Weymiller, A | 1 |
| Syed, H | 1 |
| Karakelides, H | 1 |
| Bhagra, S | 1 |
| Short, KR | 1 |
| Tatpati, L | 1 |
| Barazzoni, R | 1 |
| Nair, KS | 1 |
| Khodeer, DM | 1 |
| Zaitone, SA | 1 |
| Farag, NE | 1 |
| Moustafa, YM | 1 |
| Liu, A | 1 |
| Abbasi, F | 3 |
| Kim, SH | 1 |
| Ariel, D | 1 |
| Lamendola, C | 2 |
| Cardell, J | 1 |
| Xu, S | 1 |
| Patel, S | 1 |
| Tomasso, V | 1 |
| Mojaddidi, H | 1 |
| Grove, K | 1 |
| Tsao, PS | 1 |
| Kushida, CA | 1 |
| Reaven, GM | 3 |
| Lima, NK | 1 |
| Abe, H | 1 |
| Mita, T | 1 |
| Kudo, K | 1 |
| Funayama, T | 1 |
| Tokoro, M | 1 |
| Kaga, H | 1 |
| Ikeda, F | 1 |
| Kanazawa, A | 1 |
| Hirose, T | 1 |
| Kawamori, R | 1 |
| Watada, H | 1 |
| McLaughlin, TM | 1 |
| Liu, T | 1 |
| Yee, G | 1 |
| Tsao, P | 1 |
| Cushman, SW | 1 |
| Sherman, A | 1 |
| Collino, M | 1 |
| Aragno, M | 1 |
| Castiglia, S | 1 |
| Miglio, G | 1 |
| Tomasinelli, C | 1 |
| Boccuzzi, G | 1 |
| Thiemermann, C | 1 |
| Fantozzi, R | 1 |
| Doehner, W | 1 |
| Erdmann, E | 1 |
| Cairns, R | 1 |
| Clark, AL | 1 |
| Dormandy, JA | 1 |
| Ferrannini, E | 1 |
| Anker, SD | 1 |
| Chojkier, M | 1 |
| Elkhayat, H | 1 |
| Sabry, D | 1 |
| Donohue, M | 1 |
| Buck, M | 1 |
| Marsh, AP | 1 |
| Shea, MK | 1 |
| Vance Locke, RM | 1 |
| Miller, ME | 1 |
| Isom, S | 1 |
| Miller, GD | 1 |
| Nicklas, BJ | 1 |
| Lyles, MF | 1 |
| Carr, JJ | 1 |
| Kritchevsky, SB | 1 |
| González-Ortiz, M | 1 |
| Hernández-Salazar, E | 1 |
| Kam-Ramos, AM | 1 |
| Martínez-Abundis, E | 1 |
| Biesenbach, G | 1 |
| Grafinger, P | 1 |
| Raml, A | 1 |
| Mieszczanska, H | 1 |
| Kaba, NK | 1 |
| Francis, CW | 1 |
| Gerich, JE | 1 |
| Dodis, R | 1 |
| Schwarz, KQ | 1 |
| Phipps, RP | 1 |
| Smith, BH | 1 |
| Lee, M | 1 |
| Messing, S | 1 |
| Taubman, MB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance[NCT00443755] | Phase 2 | 28 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| A Randomized, Partially Blinded, Pilot Study of the Effects of Pioglitazone on HCV RNA in Overweight Subjects With Chronic HCV Genotypes 1 or 4 Infection.[NCT01157975] | Phase 2 | 0 participants (Actual) | Interventional | 2008-10-31 | Withdrawn (stopped due to Study was completed in another site) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Body fat is reported as a percentage of body weight. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | percentage of body weight (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 1.73 |
| Placebo | -0.01 |
Body Mass Index (BMI) is a health index for comparing weight to height. BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared. The body mass index is an indication if a person is at a suitable weight for his height on an approximation of body fat. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | kg/m^2 (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 0.37 |
| Placebo | -0.21 |
Glucose (sugar) was measured in the blood and reported in milligrams per deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -19.96 |
| Placebo | 8.39 |
FFM was measured using dual energy x-ray absorptiometry (DEXA) scans and is reported in kilograms (kg). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | kilograms (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -1.13 |
| Placebo | -0.34 |
HbA1c is a measure of average blood sugar levels over the preceding 3 month period. HbA1c was measured by ion-exchange chromatography and reported as a percentage. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | percentage (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.35 |
| Placebo | 0.19 |
TNF-α is an inflammatory cytokine and is reported in picograms/milliliter (pg/mL). (NCT00443755)
Timeframe: Baseline, 3 month
| Intervention | pg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.13 |
| Placebo | 0.18 |
Insulin levels in the blood were measured by immunoenzymatic assay and reported in micro International Units per milliliter (mcIU/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | microIU/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -8.13 |
| Placebo | 1.38 |
Insulin sensitivity was measured the morning after an overnight fast during an in-patient stay in the Clinical Research Unit & was determined by the mean GIR necessary to maintain euglycemia during a hyperinsulinemic (1.5 mcIU/kg of FFM per minute)-euglycemic (85-95 mg/dL) clamp. The clamp is an 8 hour process where a hand vein is catheterized to collect blood samples and intravenous lines are used to infuse glucose, saline, insulin, phenylalanine and amino acid solutions at at pre-specified times/rates. The mean GIR was calculated as the rate per kilograms of fat-free mass (FFM) during 4 hours of steady-state (hours 4-8 of the 8 hour clamp) reported as micromols/kilogram of FFM per minute. The FFM was measured by dual-energy x-ray absorptiometry (DEXA) scan. Insulin was infused with 5% essential amino acid solution (3mL/kg of FFM/hour) to prevent the insulin-dependent decrease of amino acids during insulin infusion. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | micromols/kg of FFM/minute (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 17.95 |
| Placebo | 1.68 |
Adiponectin is an anti-inflammatory cytokine and is reported in milligrams per milliliter (mg/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 9.10 |
| Placebo | 0.46 |
CRP is an inflammatory cytokine and is reported in milligrams per deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.19 |
| Placebo | -0.15 |
IL-6 is an inflammatory cytokine and reported in picograms per deciliter (pg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | pg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.99 |
| Placebo | -1.42 |
Fibrinogen was measured by thrombin clotting rate assay (Beckman Coulter, Inc. Brea, California) and reported in milligrams/deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 14.00 |
| Placebo | -18.62 |
PAI-1 was measured by enzyme-linked immunosorbent assay (Diagnostica Stago Inc., Parsippany, New Jersey) and reported in nanograms per milliliter (ng/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | ng/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -34.17 |
| Placebo | 8.15 |
Change in lipids were measured by the change from baseline to 3 months of triglycerides, high-density lipoprotein cholesterol (HDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). All were reported in milligrams/deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Triglycerides | HDL-C-Cholesterol | Non-HDL-Cholesterol | |
| Insulin Sensitizer Therapy | -15.58 | 4.33 | -7.50 |
| Placebo | 17.77 | -0.31 | 4.62 |
1 review available for pioglitazone and Overweight
| Article | Year |
|---|---|
Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Melli | 2014 |
8 trials available for pioglitazone and Overweight
| Article | Year |
|---|---|
Effect of pioglitazone treatment on brown adipose tissue volume and activity and hypothalamic gliosis in patients with type 2 diabetes mellitus: a proof-of-concept study.
Topics: Adipose Tissue, Brown; Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fl | 2019 |
Effect of insulin sensitizer therapy on amino acids and their metabolites.
Topics: Adult; Amino Acids; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose C | 2015 |
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population.
Topics: Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hospitalization; Humans; Hypogl | 2012 |
Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study.
Topics: Adult; Antiviral Agents; Blood Glucose; Chemical and Drug Induced Liver Injury; Cytokines; Female; G | 2012 |
Resistance training and pioglitazone lead to improvements in muscle power during voluntary weight loss in older adults.
Topics: Aged; Aging; Body Composition; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycemic Agen | 2013 |
Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance.
Topics: Body Mass Index; Double-Blind Method; Energy Intake; Fasting; Glucose Intolerance; Humans; Hypoglyce | 2007 |
Improvement of glycemic control after a 3-5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy.
Topics: Adult; Blood Glucose; Body Mass Index; Chi-Square Distribution; Data Interpretation, Statistical; Di | 2006 |
Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease.
Topics: Adult; Aged; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Fasting; Female; Hemo | 2007 |
8 other studies available for pioglitazone and Overweight
| Article | Year |
|---|---|
Early life adversity blunts responses to pioglitazone in depressed, overweight adults.
Topics: Adult; Adverse Childhood Experiences; Antidepressive Agents; Child; Depressive Disorder, Treatment-R | 2019 |
Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10-month withdrawal of pioglitazone in patients with Type 2 diabetes.
Topics: Aged; Anemia; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Drug Monitoring; Erythrocy | 2014 |
Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE-RAGE axis and inhibition of apoptosis.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Cardiotonic Agents; Diabetes Mellitus, Type 2; Diabeti | 2016 |
Effect of Pioglitazone on Cardiometabolic Risk in Patients With Obstructive Sleep Apnea.
Topics: Adult; Aged; Apolipoproteins A; Apolipoproteins B; Blood Glucose; C-Reactive Protein; Cholesterol, H | 2017 |
Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone.
Topics: Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Fem | 2009 |
Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Myotonic Dystrophy; O | 2009 |
Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue.
Topics: Adipogenesis; Adult; Aged; Blood Glucose; Cell Count; Cell Size; Humans; Hypoglycemic Agents; Insuli | 2010 |
Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation.
Topics: Administration, Oral; Animals; Cholesterol, Dietary; Dietary Carbohydrates; Disease Models, Animal; | 2010 |